An unblinded, uncontrolled, single-center preliminary clinical study to evaluate the safety and efficacy of chimeric antigen-receptor engineered T cell immunotherapy (CART) targeting CD19/CD20/CD22/CD33/CD123/CLL-1/ CD138/BCMA/ CD30 and other cell surface biomarkers in the treatment of hematologic malignancies with positive corresponding biom

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2020
This article has no abstract
Epistemonikos ID: 2d828034946eb2ab7abe956ecc9b59f861cd8f4b
First added on: Apr 07, 2025